In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).